Samuele Tardito

Dr. Samuele Tardito

Oncologia Molecolare ed Angiogenesi, IRCCS Ospedale Policlinico San Martino, Genoa, Liguria, Italy
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Autoimmunity Reviews
Verified
Journal Article
Closed access
Samuele TarditoSamuele Tardito
Samuele Tardito
GMGiulia Martinelli
Giulia Martinelli
SSStefano Soldano
Stefano Soldano
SPSabrina Paolino
Sabrina Paolino
GPGreta Pacini
Greta Pacini
MCMaurizio Cutolo
Maurizio Cutolo


Verified
Journal Article
Open access
PDF file
Samuele TarditoSamuele Tardito
Samuele Tardito
SMSerena Matis
Serena Matis
MZMaria Raffaella Zocchi
Maria Raffaella Zocchi
Roberto BenelliRoberto Benelli
Roberto Benelli
Alessandro PoggiAlessandro Poggi
Alessandro Poggi
Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. Therefore, the need for new therapeutic strategies is still a challenge. Surgery and chemotherapy represent the first-line interventions; nevertheless, the prognosis for metastatic CRC (mCRC) patients remains unacceptable. An important step towards targeted therapy came from the inhibition of the epidermal growth factor receptor (EGFR) pathway, by the anti-EGFR antibody, Cetuximab, or by specific tyrosine kinase inhibitors (TKI). Cetuximab, a mouse–human chimeric monoclonal antibody (mAb), binds to the extracellular domain of EGFR thus impairing EGFR-mediated signaling and reducing cell proliferation. TKI can affect the EGFR biochemical pathway at different steps along the signaling cascade. Apart from Cetuximab, other anti-EGFR mAbs have been developed, such as Panitumumab. Both antibodies have been approved for the treatment of KRAS-NRAS wild type mCRC, alone or in combination with chemotherapy. These antibodies display strong differences in activating the host immune system against CRC, due to their different immunoglobulin isotypes. Although anti-EGFR antibodies are efficient, drug resistance occurs with high frequency. Resistant tumor cell populations can either already be present before therapy or develop later by biochemical adaptations or new genomic mutations in the EGFR pathway. Numerous efforts have been made to improve the efficacy of the anti-EGFR mAbs or to find new agents that are able to block downstream EGFR signaling cascade molecules. Indeed, we examined the importance of analyzing the anti-EGFR antibody–drug conjugates (ADC) developed to overcome resistance and/or stimulate the tumor host’s immunity against CRC growth. Also, patient-derived CRC organoid cultures represent a useful and feasible in vitro model to study tumor behavior and therapy response. Organoids can reflect tumor genetic heterogeneity found in the tissue of origin, representing a unique tool for personalized medicine. Thus, CRC-derived organoid cultures are a smart model for studying the tumor microenvironment and for the preclinical assay of anti-EGFR drugs.

13 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Samuele TarditoSamuele Tardito
Samuele Tardito
MZMaria Raffaella Zocchi
Maria Raffaella Zocchi
Roberto BenelliRoberto Benelli
Roberto Benelli
Fibroblasts are incredible cells

6 December 2023 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
AEAndrea Escelsior
Andrea Escelsior
MMMartino Belvederi Murri
Martino Belvederi Murri
BSBruno Sterlini
Bruno Sterlini
Samuele TarditoSamuele Tardito
Samuele Tardito
TATiziana Altosole
Tiziana Altosole
GSGianluca Serafini
Gianluca Serafini

1 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Samuele TarditoSamuele Tardito
Samuele Tardito
SMSerena Matis
Serena Matis
Roberto BenelliRoberto Benelli
Roberto Benelli
Colorectal Cancer (CRC) is one of most frequent malignant cancers, showing high lethality worldwide